We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Topical steroid products are safe and highly effective treatments for the management of a wide range of inflammatory skin diseases but have important risks, especially with prolonged use at high potency. In the coming months, as a result of regulatory...
Substances that are classed as persistent organic pollutants (POPs) and when you're allowed to use them.
Information for patients, public and health care professionals.
Following MHRA approval of a clinical trial, early breast cancer patients on endocrine-based therapy can benefit from a study with camizestrant.
Quarterly updates to the emergency presentations of cancer data by Public Health England.
Find out if the goods you're declaring to inward or outward processing are classed as sensitive goods.
How to support patients in accessing population screening programmes and obtaining screening results.
Requesting comments on draft Stockholm Convention proposals for 3 chemical substances.
A patient alert card is being introduced for men taking finasteride to help raise awareness of the risk of psychiatric side effects and sexual dysfunction, including the potential for sexual dysfunction to persist after treatment has stopped. Healthcare professionals are...
Product Safety Report for Vixa Skineal Steroid Cream presenting a serious chemical risk.
These documents describe the NHS prostate cancer risk management programme (PCRMP) and its associated prostate specific antigen (PSA) test.
Product Safety Report for PTS Packers and Providers Pvt Surfaz-SN Triple Action Cream presenting a serious chemical risk.
This advice has been written by the Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG) at the request of the Medicines and Healthcare products Regulatory Agency (MHRA – UK regulator). It is in the form of questions, asked of...
Draft proposal to list chlorinated paraffins with carbon chain lengths in the range C14-17 and chlorination levels ≥45% chlorine by weight as a persistent organic pollutant (POP).
Information for healthcare professionals, patients, and the public.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).